Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Putnam Global Health Care A PHSTX
- NAV / 1-Day Return 65.29 / +0.57 %
- Total Assets 1.8 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.070%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment —
- Status Open
- TTM Yield 0.15%
- Turnover 41%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:17 PM GMT+0
Morningstar’s Analysis PHSTX
Will PHSTX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 60.9
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 8.86 | 158.6 Mil | Healthcare |
UnitedHealth Group Inc | 8.46 | 151.5 Mil | Healthcare |
AbbVie Inc | 7.08 | 126.8 Mil | Healthcare |
Intuitive Surgical Inc | 6.72 | 120.3 Mil | Healthcare |
AstraZeneca PLC | 6.43 | 115.2 Mil | Healthcare |
Novo Nordisk A/S Class B | 5.66 | 101.3 Mil | Healthcare |
Boston Scientific Corp | 4.92 | 88.1 Mil | Healthcare |
Innoviva Inc | 4.86 | 87.1 Mil | Healthcare |
Net Cash | 4.37 | 78.3 Mil | Cash and Equivalents |
Thermo Fisher Scientific Inc | 4.29 | 76.8 Mil | Healthcare |